Tvardi Therapeutics Advances Next-Generation Oral STAT3 Inhibitor TTI-109 Toward IND in Inflammatory Bowel Disease Following FDA Pre-IND Feedback
New analysis of Phase 1 exposure data supports the potential for sustained STAT3 inhibition at proposed clinical doses, with minimal predicted effect on STAT1 and STAT5 New analysis of Phase 1 exposure data supports the potential for sustained STAT3 inhibition at proposed clinical doses, with minimal predicted effect on STAT1 and STAT5